Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering gene therapy solutions for cardiovascular diseases. Headquartered in South San Francisco, California, the company leverages a proprietary adeno-associated virus (AAV) platform to create potentially curative treatments for genetic heart conditions. Its lead program, TN-201, is a gene therapy currently in phase 2 clinical trials targeting myosin binding protein C3-associated hypertrophic cardiomyopathy. Additional pipeline candidates include TN-401, a gene therapy in phase 1 trials for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, and TN-301, a small molecule therapeutic for heart failure with preserved ejection fraction. The company also develops gene therapy approaches for dilated cardiomyopathy and heart failure stemming from prior myocardial infarction. Tenaya operates primarily in the United States and collaborates with research partners to accelerate development timelines and expand scientific capabilities. The company's management team combines expertise in gene therapy, cardiovascular biology, and biopharmaceutical development to address unmet medical needs in inherited heart diseases.